Dna X (SONM) Receivables (2018 - 2026)

Dna X (SONM) has 9 years of Receivables data on file, last reported at -$4.0 million in Q1 2026.

• Quarterly Receivables fell 135.31% year-over-year to -$4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.0 million (down 135.31% YoY) and the FY2024 annual result came in at $4.5 million, down 82.79% from the prior year.
• Receivables retreated to -$4.0 million in Q1 2026, from $16.0 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $33.6 million in Q3 2023 to a low of -$4.0 million in Q1 2026.
• A 5-year average of $16.2 million and a median of $15.8 million in 2024 frame the typical range for Receivables.
• Annual changes were most pronounced in 2023 — Receivables soared 321.31% — and 2026, when it tumbled 135.31%.
• Tracing SONM's Receivables over 5 years: stood at $24.8 million in 2022, then increased by 5.84% to $26.3 million in 2023, then plunged by 85.24% to $3.9 million in 2024, then surged by 313.96% to $16.0 million in 2025, then tumbled by 124.87% to -$4.0 million in 2026.
• The last three Receivables figures came in at -$4.0 million (Q1 2026), $16.0 million (Q3 2025), and $9.8 million (Q2 2025), per Business Quant data.